Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it has successfully completed its acquisition of Decibel Therapeutics, Inc., strengthening the company’s gene therapy and auditory programs. The acquisition of Decibel builds on prior collaboration between the companies and includes three ongoing .
Regeneron (REGN) Completes Acquisition of Decibel Therapeutics streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
TARRYTOWN, N.Y., Sept. 25, 2023 Regeneron Pharmaceuticals, Inc. today announced that it has successfully completed its acquisition of Decibel Therapeutics, Inc., strengthening the company’s.
TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT , dated as of August 8, 2023, is entered into by and among Regeneron Pharmaceuticals, Inc., a New.
Proposed acquisition builds on existing collaboration between Decibel and Regeneron, will accelerate and further resource key gene therapy programs for hearing loss Decibel’s lead.